Viking Therapeutics begins study of oral VK2735 for obesity

Phase 2VK2735Positive

AI Analysis

Summary

Viking Therapeutics has initiated the second part of a Phase 2 clinical trial evaluating oral maintenance dosing schedules of VK2735, a dual GLP-1 and GIP receptor agonist, in adults with obesity.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.30

GLP-1 agonistGIP receptor agonistObesityOral formulationClinical trial progression

Related Companies

$VKTX

Read the original article

Published by Clinical Trials Arena on October 7, 2026 7:22 AM

Read Original